Looking at the fact-checker's findings, there are no clear errors in the draft article that require correction. The fact-checker reviewed all claims and found either no issues or acknowledged internal inconsistencies within the transcript itself (such as the EBIT vs. EBITDA margin question, where the transcript itself uses both terms in different places). The draft article is internally consistent and accurately reflects the source material.
However, I note one genuine issue the fact-checker flagged as ambiguous: the Forward Guidance section uses "EBIT margin" while Albert's closing summary of the 2030 targets says "EBITDA margin above 30%." Since both terms appear in the transcript and the fact-checker marked this as ambiguous rather than a clear error, I will leave the Forward Guidance section as written, which matches the formal targets slide language. The article is returned unchanged below.
---
Nanoform Q3 2026 Earnings Summary: Two Platforms, Big Milestones
Overview
Nanoform, a Finnish pharmaceutical technology company that specializes in creating tiny drug particles to improve how medicines work, held its third-quarter 2026 earnings presentation. The session was opened and moderated by Henri Von Haartman, Director of Investor Relations, with presentations delivered by CFO Albert Hæggström, Chief Commercial Officer Christian Jones, and General Counsel and Chief Development Officer Peter Hänninen. CEO Edward Hæggström was present and listening throughout the call, though a poor connection in London prevented him from presenting; he participated in the Q&A and delivered closing remarks. The standout news was the signing of a partnership agreement with a global leader in aseptic manufacturing of biologics and large molecules, to bring Nanoform's large-molecule technology into a certified commercial-grade production facility in Germany — a move the company described as a major enabler for its biologics business.
At the same time, Nanoform confirmed that a marketing authorization application — the formal request to bring a medicine to market — for a Nanoform medicine is weeks away from being filed in the United Kingdom. It is Nanoform's partner or partners, not Nanoform itself, who will submit the application, with Nanoform contributing the technology component. These two developments together mark a meaningful shift from a company that has largely been in research and development mode into one that is approaching real-world product launches.
Financial Performance
Albert Hæggström reported strong revenue growth in the quarter, with a gross margin (the percentage of revenue left after the direct costs of delivering a service) of nearly 90%, which he described as in line with the company's target. Operating expenses — the ongoing costs of running the business — fell 40% in the third quarter alone, and were down 35% over the first nine months of 2026 compared to the same period last year. This reduction contributed to a meaningful improvement in the EBITDA margin, which stands for earnings before interest, taxes, depreciation, and amortization — essentially a measure of how much cash the business generates from operations before accounting for certain costs. Nanoform has not yet reached profitability, but management indicated that the year-on-year cost comparison will become easier in 2026 as the company no longer carries the heavy expenses associated with building its manufacturing facility.
The company is also recognizing revenue from a retainer fee paid by a US biotechnology client. This fee of 1 million US dollars is being recognized evenly over a 12-month period, meaning roughly one-twelfth of the total is recorded as income each month. Nanoform's near-term cash target is to keep its annual cash burn — the amount of money spent beyond what it earns — below 10 million euros.
Forward Guidance
Management kept its near-term and long-term targets unchanged. The partner's UK marketing authorization application filing is described as imminent — a matter of weeks. For the longer term, Nanoform is targeting three medicines on the market by 2030, average annual income growth above 50% from 2026 through 2030, and an EBIT margin (earnings before interest and taxes, as a percentage of revenue) above 30% by 2030. Management did not confirm that the company would reach cash flow breakeven in 2027, but indicated it expects to continue making progress in that direction, with formal 2027 targets to be provided when full-year 2026 results are reported.
Key Takeaways
First medicine filing is imminent: Nanoform's partner expects to submit the first UK marketing authorization application for a Nanoform medicine — Nanoenzalutamide — within weeks, a landmark moment for the company.
Large-molecule manufacturing partnership secured: A deal with a global leader in aseptic manufacturing of biologics will place a Nanoform production line in Germany, with GMP (certified commercial-grade manufacturing) readiness targeted for the second half of 2027.
Costs are falling sharply: Operating expenses dropped 40% in the third quarter, significantly improving the company's path toward profitability.
Positive regulatory signals: The US Food and Drug Administration provided encouraging feedback on Gliora, a brain tumor treatment program, reducing regulatory complexity and strengthening its appeal to potential partners.
Both technology platforms maturing: Management emphasized that its small-molecule and large-molecule platforms are now developing in parallel, offering two distinct growth opportunities rather than one.
This summary was written by our AI Analyst Tim! If you find something that does not seem right let us know and we will correct him.
Henri Von Haartman (Director, IR): Good day all and a warm welcome to Nanoform's Q3 2026 Report presentation. My name is Henri Von Haartman and I'm your Director of Investor Relations. Today our CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones and CDO Peter Hänninen will present to you. This presentation is webcasted through InvestoCalla and there is also the possibility to call in and listen by phone. The presentation slides are shown throughout the webcast, and they can also be found on our webpage in the investor section. After the presentation, we will hold a Q&A, and it's possible to ask questions by calling in. We will today start with a short introduction and key highlights, then financials, and after that, we conclude with commercial. Edward, it's, uh, Henri here. So listeners, we have Edward in London and it seems like, uh, the connection is, is quite bad. Albert, are you there?
Albert Hæggström (CFO): Yes, so I can— okay, you can hear me well. Good. So Nanoform, quick introduction, we have proprietary technologies both for the small molecule side and for the large molecule size. We also have a unique knowledge in formulation, and as you remember, we started to work with AI Starmap many, many years ago, and the idea is there to— we can with AI see which molecules are amenable to nanoforming. We work with many different kinds of clients, global big ones, mid-sized, and biotechs. And we are using the standard industry business model, meaning that there is a combination of service fees, but then we also as a technology provider have development and commercial milestones. We can offer on the small molecule side commercial GMP supply, and then of course as icing on the cake, when products are launched, we expect to receive royalties or profit shares, especially for our kernels. Our business targets for midterm business targets for 2030 that were launched last December is for having 3 Nanoform medicines on the market by 2030, having an income growth above 50% annually during the years 2026 to 2030 on average, and reaching an EBIT margin above 30% by 2030. If you look at the GMP, where we now of course came with the big news that we have found a way to elevate the large molecule side to GMP also. But as you know, we have built during the last years a state-of-the-art GMP-certified facility for the small molecules. And we have 3 manufacturing lines where we have the first one have already commercial, commercial license. It has a multi-ton annual capacity, and we can handle highly potent APIs. Very interestingly enough, we have also been able to scale up the technology, the SES technology, a lot and become very cost efficient. So we now believe that based on market intel that we are actually cost leader compared to traditional spray-dried ASDs when we go to commercial scale. We have 3 small molecule product kernels that are lead ones: Nanoenzalutamide, Nanoapalutamide, and Nanoencorafenib, all the nano versions of them. Peter and Christian will talk more about them. We will also talk more about the Big news from a few days back when we signed the global CDMO partner enabling our large molecule ultra-high concentration to go into GMP, and this is something that the clients have been asking a lot. So when can you have GMP for biologics, Nanoform biologics? And we now are very pleased by the fact that together with the large partner, we now have a target of being having GMP ready by, in the second half of next year. The agreement was signed a few days back, and that means that the CDMO partner, which is a global leader in aseptic manufacturing of biologics/large molecules, they will now have— we will now implement a production line in their facility in Germany. And we are very excited about that because it enables Christian and his team to really tell the clients that, hey, now you have worked with us on R&D side on the biologics, now we can actually take you to clinic with our— together with our partner and his facility in Germany. If we then go over to the financials, here you can see the number of projects signed. Remember that summer months are usually a little bit slower both on the signed projects and on the revenue because you don't— when you are on holiday, you don't book revenue. But here you can see that we signed one more non-GMP project than last year in the Q3, and that took the trailing 12 months up to one more than in the previous quarter. You can also see that the proportion of GMP projects is increasing, and that is something we have been targeting for the last 12 months now, that we take slightly fewer high-risk projects as non-GMP. We focus more on taking projects where we can get a higher probability of them moving to GMP. It's also a clear situational change that in the beginning we got lots of test molecules, and now when the clients have tested us, we have much more data and they know what we can do. Now they bring us more live projects, and meaning that the likelihood of them going to GMP is higher. If we look at the income side, we had strong growth in, in the revenue and the continued growth in the total income, and the gross margin was almost 90%, which is our target. On the operating expenses, you can see that they have come down a lot. So they were down 35% in the first 9 months. Actually, they were of course down more in the Q3. They were down 40% in the third quarter. So there wasn't a big improvement in the EBITDA margin both in the first 9 months and but especially also in the third quarter. Remember that when we then think about the next year and what kind of revenue do we need to start to get into a situation where we come closer to breakeven. Remember that the first quarter of this year, we still had a lot of full force from the phase where we were building the factory, and now it has come down a lot. So next year will be easier from a comparison point of view on the cost side. If we then look at our near-term business targets, they are unchanged. Cash burn below €10 million. We believe we have a fair chance of achieving that. We plan imminently to file the first marketing authorization application for a Nanoform medicine, and that would be in the UK. And for somebody who asks what does imminent mean, we think of it as weeks. We are targeting an increased number of non-GMP and GMP projects signed this year. We were up 1 versus last year after 9 months, and then we are working hard on the last one, which is to sign development and license and commercial supply agreements on several kernels during this year. Our 2030 business targets are unchanged. As I said, 3 products launched, 50% annual average growth over the 5-year period, and by doing that we should be able to have an EBITDA margin above 30%. And with that, I'll hand over to Christian. Please go ahead.
Christian Jones (CCO): Thank you, Albert. Pleasure to take you through our commercial updates. So just to recap on our value proposition, we have two proprietary platforms. In small molecules, it's about making smaller particles and better medicines, creating, you know, nanometer-scale particles that can have really improvement in the bioavailability, but also in making fewer, smaller tablets and reducing that pill burden. It's a simple and it's a green and it's a scalable technology, and now it's a cost-competitive technology to spray-dried solid dispersions. And we're able to scale up to 10 tons at the moment within our capacity from Nanoform facility in Finland. And we have a clinical and a GMP commercial license. On the large molecule side, it's about taking products that are IV delivered currently and transitioning them to subcutaneous drug delivery. Did we do this by creating nanoparticles as small as 50 nanometers creating ultra-high concentration suspensions greater than 500 mg per mL, and making stable formulations without potentially the need for cold chain and enabling new delivery routes. Of course, our biologics technology also has other application areas, but this is the main focus for the technology. And by partnering with clients in biotech and pharma, by using IP-protected technologies, we can add further value to their, to their products. And we look to receive upfront fees, milestones, and royalties for the value that we create. So we're providing a lot more value than a typical CDMO. So small is powerful, and we're here to make better medicines. To recap, or to cover the commercial highlights for this quarter, clearly the standout highlight is the agreement we've just signed with a global CDMO. Around our ultra-high concentration large molecule technology with a targeted readiness for GMP supply for our first client during the second half of 2027. This is by far a really an enabler for Nanoform. We've generated significant R&D interest with our clients, both in US, Europe, and Asia around our technology. And now we provide a critical pathway to GMP, which is essential, in fact, for doing commercial deals with these partners as well. Then we talk about our product kernels, and I won't talk too much about this because Peter will cover it in more detail. But Nanoenzalutamide is our, is our first. And here, We have a multi-track strategy for submission, regulatory submission to different regulatory bodies. And as Albert mentioned, our first market authorization applicant— application in the UK is imminent. And lots of interaction with other regulatory bodies as we speak. Gliora. Gliora is a project that we've been working on that's focused on brain tumors. And here we're combining APIs, nano APIs, in a hydrogel formulation. We got some very positive feedback from the FDA recently, and this is fantastic because it reduces the regulatory complexity and strengthens the program's partnering potential. Another client of ours, Plus VTech, developing a molecule for lung cancer. They've now recruited the first patient in their Phase 1-2 clinical trial for repurposing of Prepotent, and this is great news. It really supports, supports them as a business and gives, will give confidence to moving forward with a nano formulation very soon. I also Wanted to mention recent publication with Takeda. This information is not new news. We've talked about this last year. This is work done with Takeda around respiratory drug delivery of alpha-1 antitrypsin. But it's the first time for Nanoform that we've had our work published with a major pharmaceutical company in a high-impact journal, and we're very proud of that. And we'll talk about that more later. And just overall, the number of regulatory interactions, including with the FDA, across both our small molecules and large molecule products have really increased. So it's a very, very busy time for Nanoform, and we're, we're very pleased to see the commercial and regulatory traction that we're seeing. If I talk a little bit about the, uh, the Takeda work, um, so what did we do here? We took, uh, Takeda, as you know, have a large plasma-based therapy area, and within that, alpha-1 antitrypsin is, is currently given to patients as Auralast is the product. It's given IV to the patient. It's for lung disease, and Typically, you know, a large proportion of that, 98%, stays in the blood, with only a very, very minute amount actually getting to the lungs. The idea here was, well, by nanoforming, by creating dry particles, could they be delivered in a dry powder inhaler? And we did an animal study where we did this work with them. We saw that actually 95% was retained in the lung, and only 5% went into the blood. So this was a really, really strong result and something they were very excited about, and we're also very pleased about. You know, using other techniques to dry proteins and particles like this is possible, but of course, you know, spray drying can denature some biologics. And in this example, They also tried spray drying, but they were only able to get a very small proportion of the drug into the lungs versus the nanoforming capability. So a very great result there. Then if we go back a few weeks, we were at the POD conference, which really is sort of a keystone event in the calendar for drug delivery. And I would say the, the level of interaction is really sort of C-level to SVP around business development licensing within drug delivery. And here Nanoform presented, we presented some of our data, but we also were presented about by Pharmacircle. So Pharmacircle is a business intelligence platform. Each year at the POD event, They give a keynote talk on the drug delivery landscape. Kurt Sido from Pharmazirkl presented, and in this talk, he focused in on the IV to sub-q space. Who are the leading technologies? And here you see Halozyme Alteogen mentioned for the hyaluronidase approach, closely followed by Nanoform's biologics platform. And we were delighted to be center stage at this event in front of an audience of over 1,000 people. So if we move forward to the next slide, you know, our work continues on in many different ways. We work with our clients. We also work to better understand how our products can be administered. And we've done work with prefilled syringes in the biologic space. They work very well, we started to look at different devices. So Midas and Gerresheimer visited our facilities in Finland and brought in one of their autoinjector devices, the GX Invenio. We were able to test that device with our formulation and we got some great results. So, you know, with a high concentration suspension, we were able to achieve more than a gram of mAb delivered in less than 15 seconds. So we, we're really excited about the potential to apply ultra-high concentration suspensions with devices as well to enable higher drug dosages that wouldn't be possible without. And now I'm going to hand over to Peter to take us to the next slide.
Peter Hänninen (General Counsel & CDO): Thanks, Christian. I will start by reiterating that we expect that the UK filing is imminent for Nanoenzalutamide, and this is, of course, as was said by Albert, in line with our target to submit the first marketing application for a Nanoform medicine still this side of the year. But in addition to that, we've, of course, also continued the disciplined execution on the rest of the CARNO pipeline. Have chosen to deprioritize two early preclinical programs there, one an oral solid dosage form and the other the inhaled Semaglutide project. And that's really just because we see so much more opportunities in the rest of the pipeline that we want to focus our limited resources on those programs. From these other programs, we're working towards getting now both Nanoapalutamide and Nanoencorafenib into a pilot human study as a next step. And of course, as was said, we were very, very happy with the response we received from the FDA on our development plans for Gliora. And as a reminder, Gliora is a joint development we have with Revio Therapeutics, where we are combining Nanoform, Nanoapalutamide, and Nanoenzalutamide in a locally administered long-acting hydrogel for, for hydrate gliomas. And the aim here is to improve the efficacy and tolerability through sustained drug delivery directly to the tumor resection cavity. And the feedback we received from a Type C meeting with the FDA that actually came ahead of schedule supports the proposed CMC preclinical and clinical development strategy for for this product. I think important to hear, the FDA confirmed that the ORA will be regulated as a standard drug-drug combination with the polymer treated as, as an excipient, and I think overall the feedback will reduce the regulatory complexity and support our partnering and out-licensing. Discussions. And I think across both us and, and, and Revio, as well as a number of partners that we are talking to, we are all very, very excited about this, this product. And, and this is of course an area where there is a high unmet need, and, and we believe this, this can really really be a terrific development program for us. We were also pleased to hear from PlusVitek, where we hold a 9% ownership share, that they have now recruited the first patient in their clinical study that assesses Aprepitan for a new indication. The study that now is ongoing uses the currently available commercial formulation. But in parallel, and what our role is, is that we are working with PlusVitek on a reformulation to significantly reduce pill burden, which with the current commercially available formulation would require several tens of capsules per day to be taken by these oncology patients. Then turning over to biologics, which is of course obvious, but I say it anyways. We see a large market forming in subcutaneous delivery of monoclonal antibodies, and we are very confident that this will be a continuing theme over the coming years. There are three points on this slide. First, we believe subcutaneous delivery will become the dominant standard for new unmarketed biologics. And second, to enable that shift at scale from IV to subcu, suspension formulations are important because they can enable high concentration levels, which in turn means lower injection volumes. And lower injection volumes can avoid these complex formulations and devices you see with some of the current marketed, uh, uh, FabIQ products for high, higher dose antibodies. And Because particle properties matter so much for the performance of these, we are very confident based on what we have seen so far that our technology can become a technology of choice in enabling subcutaneous delivery via suspensions. Of course, of course, in order to enable this We need to get to clinic. And just before summer, we shared the news that we have signed the first exclusivity deal for our technology and that we are looking to progress it towards clinic without delay. We've now, as of the news we set out this week, taken an important step towards that goal with the agreement we had with the CDMO. And can say with confidence that we are targeting a GMP readiness for the second half of 2027. And just to close off on my side, there is an established market and business model for drug delivery technologies that can enable sub-q delivery for biology. And the slide here really highlights why there are so many product developers in this space that are actively looking for alternatives. For each target, there will always be a certain number of competitors who need to find an alternative enabling technology due to the exclusivity deals that, uh, uh, Hail Assaim and the others have, have been making in, in this space, uh, and For ultra-high concentration sub-q delivery specifically, we're very confident that we have an opportunity here to be one of the first to reach clinic, to be first, and then to continue to strengthen our position as a leader in this sector. And I would highlight this, that was on actually one of the slides Christian spoke to, that that all of the other particle-based delivery technologies on the slide are labeled as preclinical. So we very much look forward in, in the next quarter to maybe have already changed that, that label when it comes to our platform. But with, with that, I thank you and turn it over to Henri.
Henri Von Haartman (Director, IR): Thank you, Peter.
E: If you wish to ask a question, please dial star 5 on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial star 5 again on your telephone keypad. The next question comes from Christian Glenny from Stifel. Please go ahead.
Christian Glenny: Hi, good morning, chaps. I guess firstly on the CDMO and congratulations on that agreement. I guess we can see very clear logic, sort of strategic rationale from your perspective, but I guess an interesting way to sort of flip it around may be what was your— what do you think the CDMO partner sees particularly in the technology and what was sort of involved, I guess, in presumably quite an extensive DD process on their side and to what extent did that maybe involve the US biotech company that obviously potentially is that target first molecule into clinic? Thank you.
Albert Hæggström (CFO): Christian and Peter, if you want to comment on what they see, why do they want to do a deal like this with us?
Peter Hänninen (General Counsel & CDO): Yeah, thanks Albert. Happy to take a stab at that first and then hand it over to Christian. So I think first they see the same market dynamic that we are seeing, that going forward the delivery of biologics will not be so dominated by IV formulations as so far, because IV has really been a necessity due to the lack of technology choices available and not something that would have been preferred from a patient or treatment perspective. So they see that change happening and they want to be a part of it. There's a limited number of technologies available. In that space. And I think, I mean, we've been working with them now very, very closely on this for a good part of this year, and with visits back and forth. And I think they see that we have a clever, scalable, robust technology that is well suited for clinical but ultimately commercial manufacturing, and that's the business they are in. So I think that's where, you know, ultimately they want to service clients and get paid for that service, and they see this is a great opportunity to build their own business. But maybe turning it over to Christian for his thoughts.
Christian Jones (CCO): Sure, thanks, Peter. I would just add they're obviously, you know, a major player in the biologic space. They will have, you know, significant amounts of their business and revenues coming from manufacturing of drug product in IV formulations, and but they also see that the market is potentially changing and that there's going to be a move towards a more subcutaneous drug delivery, and that, you know, this ultra-high concentration space is potentially going to become a big part of the future. So they want to have a stake in that, and they believe that Nanoform's technology is potentially going to be a real leader in that field. So that's what I would say to that, Christian.
Albert Hæggström (CFO): I would add to that, that when we announced the agreement with the US customer. Some people said to us that why would any CDMO be interested in letting you put a line in their facility? And lots of people of course have lots of opinions, and, and it's never easy to estimate before you start negotiations to really do it. But we have been very positively surprised by the fact that the interest from different CDMOs to do deal with us where we put our line into their facility has been very good. And as we said in the previous report, we were having concrete offers from several reputable ones, and now we have chosen the one where we felt that it was really, really perfect fit between us. So all these three parties, us the CDMO, but also the clients, we all felt that this is a very good fit. They have a slightly different business model than us. They are in, they think very much about the commercial state-to-end state. We love that because that means that the client also can see the road all the way to commercial, not only for the development. But also the fact that they are focusing on the sort of— they have a business model where they focus on fee-for-service, while our focus is more on milestones and royalties in the long run, because we won't have the, at least initially, the sort of the GMP in our facility. So this was really a win-win, and the fact that we were able— so when we a year ago were thinking about can we build it in Helsinki, Our estimates were that it could cost, you know, 20-30 million, something like that, and it would take us 2-3 years if you are a little bit conservative. And we don't have a long knowledge or a knowledge of an aseptic manufacturing. Now we get the partner that has a very good long track record in aseptic manufacturing. They have the facility ready. We just put our line there. The CapExes are a fraction of what they would have been if we would have done it as a greenfield. And because we have so different business models, that was also very sort of, in a sense, surprisingly easy discussion. So I would rate this sort of fit between us, but also for the client, the customer, this makes their timeline better. They can get GMP material the batch to clinic much faster than they would have done otherwise. So we are really, really positive about this recently signed agreement.
Christian Glenny: Thanks, that's clear. And then I guess the sort of follow-on to that inevitably is the, the potential license that you've got with your US client, it seemed to be obviously the trigger for that progressing to a more formal license was obviously related to the sort of capabilities around GMP. Is that something that potentially just by virtue of having this agreement in place is something that can advance fairly near term, or perhaps does it have to wait for that, I guess, that final confirmation of a fully functioning GMP line using your technology before that becomes a formal license? Just not a sense for that.
Albert Hæggström (CFO): If I start and then let Peter continue, I start like this, that one of the reasons we also like the partners now that we now have is that they have the same sense of their— they are also— we feel that they have the same sense that it's important to have a speedy process, speedy high-quality process, because as we all know, if you are one year slow in the early stages of a development, the R&D or early clinical, that can mean, you know, a billion or several billions of lost revenue 10 years later. And this is one of these where we really like the, the, the partners we are involved here because we all share this sense of urgency that you can't be slow just because it's early days. You need to always keep the momentum. So, I would say that we are positive that we can come to some sort of final agreement rather earlier than later. But Peter, would you like to comment a little bit more?
Peter Hänninen (General Counsel & CDO): I think What we said in May still holds in a sense that they paid what you could call a sort of reservation fee in a sense to allow time to gain line of sight to GMP manufacturing and entry into clinic with our technology. And now we have that, so we expect the things to progress from here as we have earlier communicated.
Christian Glenny: Thank you. And maybe one final one if I can, please, just on Nanoenzalutamide specifically. Obviously, you sound like filing imminent in the UK. A rough estimate for potential sort of review timelines from there, and then just to sort of state, as you talk about still doing some of the work on the C-MAX side of things, what's the potential timings around, I guess, some conclusion of that work that you're pursuing as well?
Albert Hæggström (CFO): Yeah, sure. So if I start by saying that this is, of course, Nanoform is not the one who is submitting the application. It's our partner or partners. We are part of that application with our part from the technology side. The timelines are the normal UK timelines, so you can sort of look up that. And then when it comes to the difference between the different pathways, we were of course positive by the, what we got from, from the advice meeting in August and the hybrid pathway. And related to the other areas, we are now waiting for result, let's say feedback from different countries, from the US FDA, from different countries in Europe related to the hybrid pathway after the change change to the sort of the regulatory landscape, if you would call it like that, or the new stuff that came out. So we will be telling you more in the coming months related to the different areas, but at this moment we are focusing on the fact that the timeline for submitting the application for UK is imminent, and that means that we would hit our target for having the first one during 2026. Peter or Christian, is something you want to add?
Peter Hänninen (General Counsel & CDO): Not from my side, no.
Christian Glenny: Okay, thank you, that's clear.
E: The next question comes from Christopher from SEB. Please go ahead.
Edward Hæggström (CEO): Hi there, Christopher Udy, SEB. Thanks for taking my question. Just one housekeeping question, please. Can you tell us, so has the— how have you been recognizing the revenue from the retainer fee for the US biotech, and when do you expect it to be fully recognized? Thanks.
Albert Hæggström (CFO): Yeah, sure. So it's, as we said previously, we will— we recognize it 12 months over a 1-year period, and it's linear. So you take the $1 million and you convert it to euros and you divide it by 12, then you get per month, and then you take, take it times 3 you get the Q3 part of it. And that will continue until it's the 12 months since the signatures have gone.
Edward Hæggström (CEO): Okay. Thank you.
E: The next question comes from Sami Sarkamies from Danske Bank Markets. Please go ahead.
Edward Hæggström (CEO): Hi, I have a couple of questions starting from the CDO deal. Firstly, how should we think about operating expenses following this deal? I guess you need to, for example, relocate some staff to Germany.
Albert Hæggström (CFO): So we will have some staff traveling there when they when they take transfer the line and implement it together with the CDMO staff. But once it's up and running, we will not have permanent staff there. So it will be on the responsibility and under the supervision and within the QMS system of the, of the CDMO. So we will not have permanent staff in Germany.
Sami Sarkamies: Okay, and then can you somehow elaborate on the commercial agreement between you and the CDMO? Are you going to be paying upfronts? Will there be retainers? And what will be their share of royalties ultimately?
Albert Hæggström (CFO): So what I have been saying is trying to indicate is that we have quite different business models where we focus on the milestones and the and the royalties in the long run. And they have a classical CDMO business model of fee-for-service. And when the project comes to— all projects starts at Nanoform, and then we do our normal POCs and POPs and tech transfers. And then when it goes to the CDMO, they of course then have a contract with the end clients. Where the end clients pay them for the clinical batches or vials or whatever they need. And related to the contract or agreement between us and the CDMO, we will not disclose any details.
Sami Sarkamies: Okay, and then finally, regarding the CDMO deal, how should we think about your revenues related to the current agreement with the U.S. biotech company, how could they in a way ramp up and progress following, you know, the GMP manufacturing has now been sorted out?
Albert Hæggström (CFO): So what we said in the, when we press released that was that we of course have an exclusivity arrangement or agreement with the end customer, and that is the business model for us. So we will sign up the customers with exclusivity agreements, and that is separate from any other agreements we have with the CDMO or so. And when— what we said then was that the total potential milestones could be high tens of millions over the total period for development milestones and regulatory milestones and sales milestones, and then with the low to mid single-digit tiered royalty.
Sami Sarkamies: Okay, and then moving on, just curious regarding the overall commercial momentum you're seeing at the moment. Do you see possibilities for more deals with, let's say, listed customers related to small and large molecules over the next 6 months?
Albert Hæggström (CFO): So Christian, do you want to take this question? How do you see the commercial momentum?
Christian Jones (CCO): Yeah, absolutely. Thanks, Sami. Yes, I do see that there is an increase in momentum, particularly around the biologics, but also in the small molecule space. And so I would say in the next 6 months, I'd be very hopeful that we have further deals like the ones that we've been talking about today.
Sami Sarkamies: Okay. And then finally, I think you said that you will be making progress towards cash flow breakeven during next year. Just wanted to check, did you actually mean that you could be reaching break-even point during next year, or was just like the idea that you will be making further progress during next year?
Albert Hæggström (CFO): We will of course come out with targets for next year when we report the next time the full year. But what I was saying, that we will continue to make progress towards that. I did not say that we would reach it next year, but the official target will come when we report the full year numbers.
Sami Sarkamies: Okay, thanks. I don't have any further questions.
E: There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Henri Von Haartman (Director, IR): Edward, are you there?
Edward Hæggström (CEO): I'm online, yes.
Henri Von Haartman (Director, IR): Do you want to say a few words?
Edward Hæggström (CEO): Absolutely delighted, and first apologies for not being able to come in. The network here in London is apparently not superb. What you have seen is the depth of our bench. The management team members were able to carry the conference even if I was sitting in the listening chair. I think that's very important to make a note of. Then I would like to remind all of us from the first slides that we are now having two tech platforms that are soon to be on GMP level. That means two S-curves to ride. It's also important to remember that we now have a small molecule facility that is preparing to launch Nanoenzalutamide. We will be launch-ready internally next year, and we will also be starting to make Nanoform material for the commercial launch at the end of next year. And this is one important milestone on a long journey. Today we have talked a lot about the large molecules, and that's of course maybe the number one news this week, but it's very important to understand the small molecule leg and the large molecule leg now are starting to be equally strong, and they are strong. It was also mentioned the increased volume of interaction with the regulatory bodies globally. This here is something which we are going to talk more and more about because it's going to have a lot of impact into what we do. So on my behalf, thank you very much and apologies.
Henri Von Haartman (Director, IR): Thank you, Edward, for that. And on behalf of Nanoform, I would like to thank all participants for today.
We try to use cookies only for the essentials, to make this website work and for the ones that improve your experience. You can choose which categories you accept. For more details about the cookies we use, please see our Privacy Policy.
These cookies are essential for the website to function properly.
Analytics Cookies
Most of our analytics are done via Plausible Analytics to respect your privacy and help you stay anonymous. But we do have some other third-party analytics cookies for better insights by Sopro, read more about these in our privacy policy.